TSTickerStarGet alerts

bioAffinity reports 235 CyPath Lung tests in October 2026, up 29% year over year

No financial results were reported, so there is no beat, miss, or in-line comparison with the supplied FY2026 guidance. bioAffinity reported 235 CyPath Lung tests performed in October 2026, up 29% from October 2025, and said the volume was the highest monthly level for the test. October volume was approximately 45% of all tests performed in Q3 2026.

Share this story

Key takeaways

  • Testing volume: bioAffinity reported 235 CyPath Lung tests performed in October 2026, the highest monthly testing volume disclosed for the test.

  • Year-over-year growth: October 2026 testing volume increased 29% compared with October 2025.

  • Quarterly contribution: October 2026 testing volume represented approximately 45% of all tests performed in Q3 2026.

  • Physician utilization: The company reported continued growth in testing by established and newly ordering physicians.

  • Commercial expansion: The company said it expanded its sales team and is pursuing direct physician engagement, distribution relationships, and opportunities within government healthcare systems.

Key metrics

CyPath Lung tests performedOctober 2026
23529%
October testing volume as a share of total Q3 2026 testsOctober 2026
approximately 45%

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow BIAF in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert